(Q39830190)

15 September 2017

title

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease (English)

1 reference

15 September 2017

1 reference

E Monteagudo

1

1 reference

15 September 2017

M Fonsi

2

1 reference

15 September 2017

X Chu

3

1 reference

15 September 2017

K Bleasby

4

1 reference

15 September 2017

R Evers

5

1 reference

15 September 2017

V Pucci

6

1 reference

15 September 2017

M V Orsale

7

1 reference

15 September 2017

S Cianetti

8

1 reference

15 September 2017

M Ferrara

9

1 reference

15 September 2017

S Harper

10

1 reference

15 September 2017

R Laufer

11

1 reference

15 September 2017

M Rowley

12

1 reference

15 September 2017

V Summa

13

1 reference

15 September 2017

language of work or name

English

0 references

publication date

7 October 2010

1 reference

15 September 2017

1 reference

15 September 2017

volume

40

1 reference

15 September 2017

issue

12

1 reference

15 September 2017

page(s)

826-839

1 reference

Noncompartmental Determination of the Steady‐State Volume of Distribution

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Bismacrocyclic inhibitors of hepatitis C NS3/4a protease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Organic anion transporting polypeptides of the OATP/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Role of OATP transporters in the disposition of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

The epidemiology of hepatitis C infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.519061

10.3109/00498254.2010.519061

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference